DOI: 10.12688/f1000research.20419.1; PMCID: PMC7431970
Stevens-Johnson syndrome and toxic epidermal necrolysis are rare severe blistering skin reactions triggered by medications or infections. Over the last 5 to 10 years, a number of important publications have advanced understanding of these diseases and their response to treatment. Importantly, a subset of patients with disease triggered by infection has been identified as having Mycoplasma pneumoniae-induced rash and mucositis, suggesting a reconsideration of the diagnostic paradigm. We present an update on pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the broader context of cutaneous adverse drug reactions and focus on challenges and recent advances in diagnosis, management, and prevention.
DEN; RIME; SJS; Stevens-Johnson syndrome; TEN; drug eruption; drug reaction; drug-induced epidermal necrolysis; reactive infectious mucocutaneous eruption; severe cutaneous drug reaction; toxic epidermal necrolysis
Ramien M, Goldman JL. Pediatric SJS-TEN: Where are we now?. F1000Res. 2020;9:F1000 Faculty Rev-982. Published 2020 Aug 13. doi:10.12688/f1000research.20419.1
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Publisher's Link: https://doi.org/10.12688/f1000research.20419.1